In vitro intracellular IFNγ, IL-17 and IL-10 producing T cells correlates with the occurrence of post-transplant opportunistic infection in liver and kidney recipients

Table 2 Patient clinical and demographic characteristics

	Liver recipients (n = 30)			Kidney recipients (n = 31)
	NoINF (n = 12)	INF (n = 18)	P	NoINF (n = 12)	INF (n = 19)	P
Donor age (yr)	60.75 ± 3.32	58.93 ± 4.71	0.905	51.21 ± 3.171	55.67 ± 3.831	0.0171
Recipient age (yr)	51.25 ± 2.87	53.79 ± 2.37	0.282	51.58 ± 3.25	51.42 ± 2.81	0.351
Recipient gender (M/F), n (%)	14 (87.5)/2 (12.5)	9 (64.3)/5 (35.7)	0.669	10 (41.7)/2 (28.6)	14 (58.3)/5 (71.4)	0.087
Total lymphocyte (%)	15.38 ± 3.63	11.39 ± 2.08	0.397	16.09 ± 2.85	11.66 ± 2.33	0.768
Total lymphocyte (cells/mm3)	813.34 ± 163.70	750.02 ± 191.84	0.711	1121.67 ± 173.35	1073.16 ± 235.68	0.197
Total leukocyte (× 109/L)	6.29 ± 0.55	7.09 ± 1.10	0.652	8.36 ± 1.151	10.98 ± 1.331	0.0061
SGOT (U/L)	187.44 ± 97.28	117.16 ± 18.09	0.738	27.66 ± 4.61	19.17 ± 1.09	0.669
SGPT (U/L)	161.69 ± 69.20	135.56 ± 14.77	0.891	44.51 ± 9.81	27.06 ± 1.98	0.762
SALP (U/L)	177.47 ± 14.72	186.62 ± 14.40	0.847	106.84 ± 8.231	85.36 ± 2.741	0.0081
SGGT (U/L)	197.27 ± 23.651	351.28 ± 42.441	0.0051	109.97 ± 25.34	64.36 ± 11.74	0.074
Glomerular filtration (mL/min)	82.82 ± 7.36	81.28 ± 6.27	0.571	45.87 ± 2.901	72.42 ± 2.521	0.0191
Serum creatinine	0.93 ± 0.051	1.08 ± 0.061	0.0271	6.22 ± 0.60	5.83 ± 0.51	0.251
Induction therapy (thymoglobulin/basiliximab)	0(0 )/0(0)	0(0)/1(3.3)		1(8.3)/11(91.7)	4(21.1)/12(63.2)	0.161
Post-transplant therapy (TRL/TRL + MMF), n (%)	7(58.3)/5(41.7)	10(55.6)/8(44.4)	0.880	0/0/12(100)	1(5.3)/2(10.5)/16(84.2)	0.350
Maintenance therapy (TRL/TRL + MMF), n (%)	7(58.3)/5(41.7)	13(72.2)/5(27.8)	0.461	0/0/12(100)	2(10.5)/2(10.5)/15(78.9)	0.235
TRL dose (mg/d)	7.92 ± 0.281	6.67 ± 0.391	< 0.0011	13.08 ± 1.51	12.35 ± 1.37	0.179
MMF dose (mg/d)	2062.50 ± 73.451	1848.57 ± 79.001	0.0341	1620 ± 164.701	1917.89 ± 58.871	< 0.0011
Cmin TRL (ng/mL)	10.46 ± 0.69	9.61 ± 0.47	0.445	10.54 ± 1.981	6.53 ± 1.971	0.0121
Cmin MMF (μg/mL)	2.91 ± 0.601	0.97 ± 0.291	0.0161	1.07 ± 0.18	3.80 ± 1.20	0.071

¹Statistical significance. NoINF: Free-opportunistic infection study group; INF: Opportunistic infection study group; SGOT: Serum glutamic oxaloacetic transaminase; SGPT: Serum glutamic pyruvic transaminase; SALP: Serum alkaline phosphatase; SGGT: Serum Gamma-Glutamyl Transpeptidase; TRL: Tacrolimus; MMF: Mycophenolic acid.